

## Molecular Imaging Summit at SNM Mid-Winter Meeting


The SNM Center for Molecular Imaging Innovation and Translation (CMIIT) is sponsoring a 1-d Molecular Imaging Summit at the SNM Mid-Winter Meeting on Thursday, January 26, 2012, in Orlando, FL, to address the growing role of molecular imaging in dementia. Neuroimaging is poised to have a dramatic clinical impact with the advancing development of radiotracers for imaging amyloid plaques and other targets relevant to dementia. The speakers at this summit will critically assess the current state of the art in diagnostic evaluation of dementia and highlight recent key developments and controversies in the clinical translation of radiopharmaceuticals for dementia imaging. The summit, chaired by Michael Devous, MD, and myself, will continue a long-standing tradition of bringing together nuclear medicine physicians, radiologists, molecular imaging scientists, referring clinicians, and scientific experts from a range of disciplines. In addition, a speaker from the patient advocacy community will provide important and unique perspectives. Two panel discussions during the session will allow for more in-depth discussions and questions.

The following topics will be covered: key issues in the diagnosis and therapy of Alzheimer disease, overview of biomarkers in dementia including MR imaging and cere-

brospinal fluid studies,  $^{18}\text{F}$ -FDG imaging in dementia, amyloid plaque imaging, dopamine transporter imaging in dementia, and investigational radiotracers for dementia.

In addition to the continuing education (CE) session during the day, an evening non-CE panel discussion will include representatives from companies involved in phase III clinical trials of amyloid plaque imaging agents. This evening session will provide a more informal setting for conversation among participants from industry, academia, and private practice.

We hope that members of the nuclear medicine and molecular imaging community will consider joining us for this summit addressing the exciting recent advances in the molecular imaging of dementia. See [www.snm.org/mwm2012](http://www.snm.org/mwm2012) for more information and an updated list of speakers.



**Jonathan McConathy  
MD, PhD**

*Jonathan McConathy, MD, PhD  
Washington University Medical Center*

### Section 3: COUNCILS

- A. Description: The Society recognizes the need for sub-specialty interests/expertise within the field of nuclear medicine and molecular imaging. Councils provide the expertise, professional networking, and educational programs for nuclear medicine and molecular imaging professionals in respective areas and serve as a resource for development and implementation of Society policy.

### Section 4. CENTERS

- A. Mission: Center status is reserved for nuclear medicine and molecular imaging subspecialty or sub-disciplinary areas of interest, each approved by the Board of Directors. Centers provide professional networking and educational programs for nuclear medicine and molecular imaging professionals in respective areas, while simultaneously serving as a resource for development and implementation of Society policy. Leadership of centers is composed of elected members of the center and appointed members from the Board of Directors. Centers will manage Society programs and activities related to their subspecialty or sub-disciplinary areas of interest.

### Section 5. TECHNOLOGIST SECTION

- A. The Technologist Section is the organizational component of the Society specifically addressing nuclear medicine and molecular imaging technologists' issues and interests.

## ARTICLE VII HOUSE OF DELEGATES

### Section 2: RESPONSIBILITIES

- A. To develop and recommend to the Board of Directors, Society policies and programs regarding professional issues affecting nuclear medicine and molecular imaging.